thomas kurian wife allisonthomas kurian wife allison

Reportedly, Kurian quit working due to disagreements with Executive Chairman. However, it may also reflect racial/ethnic differences in the distributions of personal and family histories among breast cancer cases in the Northern California population. Data from 108,420 invasive breast cancer cases and 87,681 controls were used for the LSI analysis and for the CPD analysis conducted among ever-smokers from 26,147 cancer cases and 26,072 controls. Contribution of the Neighborhood Environment and Obesity to Breast Cancer Survival: The California Breast Cancer Survivorship Consortium. Thompson, C. A., Kurian, A. W., Luft, H. S. Diabetes and Other Comorbidities in Breast Cancer Survival by Race/Ethnicity: The California Breast Cancer Survivorship Consortium (CBCSC). Comprehensive cancer risk assessment is highly relevant to the Precision Medicine Initiative (PMI), and payers' considerations could inform PMI's efforts. View details for DOI 10.1200/JCO.2013.53.6607, View details for Web of Science ID 000337925500007. This study describes the diagnostic yield and patient experiences of MGPT in diverse populations.This multicenter, prospective cohort study enrolled participants from three cancer genetics clinics-University of Southern California Norris Comprehensive Cancer Center, Los Angeles County and University of Southern California Medical Center, and Stanford Cancer Institute-who met testing guidelines or had a 2.5% or greater probability of a pathogenic variant (N = 2,000). Logistic and linear regression models were used to evaluate for association of clinical trial engagement and patient portal message rates with primary language group.Patients with LEP had significantly lower rates of clinical trial engagement compared with their English-speaking counterparts (adjusted odds ratio [OR], 0.29; 95% CI, 0.16 to 0.51). Our hypothesis is that by combining molecular signatures with clinicopathologic features, we can elucidate the biology of breast cancer progression, and risk-stratify patients with DCIS.Targeted exon sequencing with a custom panel of 223 genes/regions was performed for 125 DCIS cases. The results of this case series suggest a reduced risk of breast cancer associated with RRSO in the immediate 5 years after surgery in women carrying BRCA1 and BRCA2 pathogenic variants, and a longer-term association with cumulative breast cancer risk in women carrying BRCA1 pathogenic variants. View details for DOI 10.1136/jmedgenet-2015-103132. Mean hazard ratios SD, and DRFS rates are reported from 1000 simulations.The simulation results closely replicated TAILORx findings, with 75% of simulated trials showing noninferiority forchemotherapy omission. Future research should identify the aspects of ACS program hospitals that are associated with higher survival and evaluate strategies by which to enhance access to and use of high-quality hospitals, particularly among African American women. A., Kurian, A. W., et al, Variation in HER2 positive rates in California by geographic region: Implications for setting pathology laboratory benchmarks. Utilization of a multigene panel should also be considered, given the additional non-Lynch germline mutation identified in this cohort. placebo in combination with nab-paclitaxel in participants with locally advanced or Impact of cancer worry did not substantively differ by test type, test result outcomes, or clinical or treatment factors. Knowing the spectrum and frequency of the founder mutations in this population will assist in the development of a cost-effective rapid screening assay, which in turn facilitates genetic counseling and testing for the purpose of cancer risk assessment. View Original Notice Allison, Thomas "Tommy" Thomas Edward "Tommy" Allison, age 75, of Gr Ho, W. K., Tai, M. C., Dennis, J., Shu, X., Li, J., Ho, P. J., Millwood, I. Y., Lin, K., Jee, Y. H., Lee, S. H., Mavaddat, N., Bolla, M. K., Wang, Q., Michailidou, K., Long, J., Wijaya, E. A., Hassan, T., Rahmat, K., Tan, V. K., Tan, B. K., Tan, S. M., Tan, E. Y., Lim, S. H., Gao, Y. T., Zheng, Y., Kang, D., Choi, J. Y., Han, W., Lee, H. B., Kubo, M., Okada, Y., Namba, S., Park, S. K., Kim, S. W., Shen, C. Y., Wu, P. E., Park, B., Muir, K. R., Lophatananon, A., Wu, A. H., Tseng, C. C., Matsuo, K., Ito, H., Kwong, A., Chan, T. L., John, E. M., Kurian, A. W., Iwasaki, M., Yamaji, T., Kweon, S. S., Aronson, K. J., Murphy, R. A., Koh, W. P., Khor, C. C., Yuan, J. M., Dorajoo, R., Walters, R. G., Chen, Z., Li, L., Lv, J., Jung, K. J., Kraft, P., Pharoah, P. D., Dunning, A. M., Simard, J., Shu, X. O., Yip, C. H., Taib, N. A., Antoniou, A. C., Zheng, W., Hartman, M., Easton, D. F., Teo, S. H. Genetic insights into biological mechanisms governing human ovarian ageing. Incidence rates for any contralateral primary cancer following an HR-negative or HR-positive tumor were higher in non-Hispanic blacks, Hispanics, and Asians or Pacific Islanders than in non-Hispanic whites.Risk for contralateral second primary breast cancers varies substantially by HR status of the first tumor, age, and race and/or ethnicity. A., O'Neill, S., Chandler, Y., Isaacs, C., Kurian, A. W., Kushi, L., Schechter, C. B., Mandelblatt, J. Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. Kurian, A. W., Antoniou, A. C., Domchek, S. M. Use of Gene Expression Profiling and Chemotherapy in Early-Stage Breast Cancer: A Study of Linked Electronic Medical Records, Cancer Registry Data, and Genomic Data Across Two Health Care Systems. It's necessary to re-evaluate these variants in large GWAS datasets.Of these 279 variants, data were obtained for 228 from GWAS conducted within the Asian Breast Cancer Consortium (24,206 cases and 24,775 controls) and the Breast Cancer Association Consortium (122,977 cases and 105,974 controls of European ancestry). Additionally, two large studies reported increased all-cancer survival with statin use. Results: The adjusted overall survival hazard ratio was 0.98 (95% CI: 0.67-1.44), indicating a similar risk of death between groups. No association was observed for breast cancer-specific mortality. cells, by stopping them from dividing, or by stopping them from spreading. By contrast, VUS results were more frequent among nonwhites, with potential significance for the impact of MGS testing by race/ethnicity.GENETICS in MEDICINE advance online publication, 27 July 2017; doi:10.1038/gim.2017.96. evaluate the safety, tolerability, pharmacokinetics and feasibility of trastuzumab emtansine Results were similar using BOADICEA.Our analysis shows that risk stratification using clinical models will likely be more accurate when based on predicted 5-year risk compared with risks based on predicted lifetime and remaining lifetime, particularly for women aged 20-39years. Relative to high-socioeconomic status (SES) non-Hispanic Whites, we observed less anthracycline and taxane use by SES non-Hispanic Whites (OR 0.63, 95 % CI 0.49-0.82) and American Indians (OR 0.23, 95 % CI 0.06-0.93), and more anthracycline use by high-SES Asians/Pacific Islanders (OR 1.72, 95 % CI 1.02-2.90). Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention. As Google lays off 12,000 employees . A nonsignificant increase in at least 1 severe/very severe toxicity report was observed for bilateral mastectomy recipients (OR, 1.2; 95% CI, 1.0-1.4).Women with early-stage invasive breast cancer report substantial treatment-associated toxicities and related burden. Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., Seto, T., Thompson, C. A., Rigdon, J., Telli, M. L., Badve, S. S., Curtis, C. N., West, R. B., Horst, K., Gomez, S. L., Ford, J. M., Sledge, G. W., Kurian, A. W. Genetic testing and results in population-based breast cancer patients and ovarian cancer patients. ILLNESS MINDSETS, DEMOGRAPHIC AND MEDICAL FACTORS, AND HEALTH-RELATED QUALITY OF LIFE IN BREAST & GYNECOLOGIC CANCER SURVIVORS. breast cancer 2008-2009 showed initial safety,tolerability and good bioavailability of both [5] By July, she received a Physician Faculty Scholars Award from the Robert Wood Johnson Foundation to fund her study, "Optimizing the use of breast cancer risk-reduction strategies by patients and physicians. Worse financial toxicity related to younger age (p View details for DOI 10.1038/s41467-020-17680-w. To study the impact of rising bilateral mastectomy rates among neoadjuvant chemotherapy (NAC) recipients in California.NAC for operable breast cancer (BC) can downstage disease and facilitate breast conservation. The reported HER2-positive percentage was higher when the population had higher stage, tumor size, grade, percent estrogen receptor negative, younger age, or lower socioeconomic status. Gomez, S. L., Press, D. J., Lichtensztajn, D., Keegan, T. H., Shema, S. J., Le, G. M., Kurian, A. W. Accuracy of BRCA1/2 Mutation Prediction Models for Different Ethnicities and Genders: Experience in a Southern Chinese Cohort. However, little is known about the context of such testing or its impact on treatment. Assuming all stage IV cancers were diagnosed at stage III, 32-80 fewer cancer-related deaths would be expected across subgroups, a relative reduction of 13-14%. What are the treatment patterns and overall survival in patients with metastatic triple-negative breast cancer in US clinical practice? We performed logistic regression to identify independent predictors of breast cancer. We projected the impact of COVID-19 on future breast cancer mortality between 2020 and 2030.Three established Cancer Intervention and Surveillance Modeling Network breast cancer models modeled reductions in mammography screening use, delays in symptomatic cancer diagnosis, and reduced use of chemotherapy for women with early-stage disease for the first 6 months of the pandemic with return to prepandemic patterns after that time. Forty-six percent (n=145) experienced a change in their care due to COVID-19. Because coronary artery disease remains the primary cause of death for women, any intervention to reduce breast cancer risk must be weighed against comorbidities and interventions affecting cardiovascular risk reduction. pertuzumab, if applicable) in patients with human epidermal growth factor receptor 2-positive Wu, A. H., Gomez, S. L., Vigen, C., Kwan, M. L., Keegan, T. H., Lu, Y., Shariff-Marco, S., Monroe, K. R., Kurian, A. W., Cheng, I., Caan, B. J., Lee, V. S., Roh, J. M., Sullivan-Halley, J., Henderson, B. E., Bernstein, L., John, E. M., Sposto, R. A Population-Based Observational Study of First-Course Treatment and Survival for Adolescent and Young Adult Females with Breast Cancer. Hodan, R. n., Kingham, K. n., Cotter, K. n., Folkins, A. K., Kurian, A. W., Ford, J. M., Longacre, T. n. Racial/ethnic disparities in survival after breast cancer diagnosis by estrogen and progesterone receptor status: A pooled analysis. Non-European populations are under-represented in genetics studies, hindering clinical implementation of breast cancer polygenic risk scores (PRSs). Associations of PRS313 (continuous, per standard deviation) with overall survival (OS) and breast cancer-specific survival (BCSS) were evaluated with Cox regression, adjusted for clinicopathologic characteristics and treatment.The PRS313 was associated with more favorable tumor characteristics. A., Kingham, K., Ford, J. M. Asian-Caucasian differences in BRCA1/2 mutation epidemiology. Over half of women reported that doctors used words and numbers to describe risk, while 24% used only words. Polygenic risk scores (PRS) have been shown to predict breast cancer risk in European women, but their utility in Asian women is unclear. View details for DOI 10.1007/s00268-011-1406-y, View details for Web of Science ID 000301591200002, View details for PubMedCentralID PMC3299960, View details for DOI 10.1200/JCO.2011.40.9938, View details for Web of Science ID 000302631300026. View details for DOI 10.1200/JCO.2015.63.5524. Chris Mellor. Surveys were linked to SEER clinical data and genetic test results. While his second oldest brotheris a pediatrician in the U.K. We concluded that further adaptation of the coverage framework will facilitate a better suited assessment of NGTS and future genomics innovations. Weldon, C. B., Liang, S., Phillips, K. A., Douglas, M. P., Scheuner, M., Kurian, A. W., Schaa, K., Roscow, B., Erwin, D., Trosman, J. R. The Impact of COVID-19 on Patients With Cancer: A National Study of Patient Experiences. This cohort will enable analyses to jointly consider a variety of clinical, lifestyle, and contextual factors in attempting to explain the long-standing disparities in breast cancer outcomes. Price, E. R., Hargreaves, J., Lipson, J. Nearly all patients (91%; 95% CI, 81% to 97%) shared results with relatives, and most patients (78%; 95% CI, 64% to 88%) reported that a relative was subsequently tested. A., Gaudet, M. M., Giles, G. G., Goldberg, M. S., Goldgar, D. E., Gunel, P. n., Haiman, C. A., Hkansson, N. n., Hall, P. n., Harrington, P. A., Hart, S. N., Hartman, M. n., Hillemanns, P. n., Hopper, J. L., Hou, M. F., Hunter, D. J., Huo, D. n., Ito, H. n., Iwasaki, M. n., Jakimovska, M. n., Jakubowska, A. n., John, E. M., Kaaks, R. n., Kang, D. n., Keeman, R. n., Khusnutdinova, E. n., Kim, S. W., Kraft, P. n., Kristensen, V. N., Kurian, A. W., Le Marchand, L. n., Li, J. n., Lindblom, A. n., Lophatananon, A. n., Luben, R. N., Lubiski, J. n., Mannermaa, A. n., Manoochehri, M. n., Manoukian, S. n., Margolin, S. n., Mariapun, S. n., Matsuo, K. n., Maurer, T. n., Mavroudis, D. n., Meindl, A. n., Menon, U. n., Milne, R. L., Muir, K. n., Mulligan, A. M., Neuhausen, S. L., Nevanlinna, H. n., Offit, K. n., Olopade, O. I., Olson, J. E., Olsson, H. n., Orr, N. n., Park, S. K., Peterlongo, P. n., Peto, J. n., Plaseska-Karanfilska, D. n., Presneau, N. n., Rack, B. n., Rau-Murthy, R. n., Rennert, G. n., Rennert, H. S., Rhenius, V. n., Romero, A. n., Ruebner, M. n., Saloustros, E. n., Schmutzler, R. K., Schneeweiss, A. n., Scott, C. n., Shah, M. n., Shen, C. Y., Shu, X. O., Simard, J. n., Sohn, C. n., Southey, M. C., Spinelli, J. J., Tamimi, R. M., Tapper, W. J., Teo, S. H., Terry, M. B., Torres, D. n., Truong, T. n., Untch, M. n., Vachon, C. M., van Asperen, C. J., Wolk, A. n., Yamaji, T. n., Zheng, W. n., Ziogas, A. n., Ziv, E. n., Torres-Meja, G. n., Drk, T. n., Swerdlow, A. J., Hamann, U. n., Schmidt, M. K., Dunning, A. M., Pharoah, P. D., Easton, D. F., Hooning, M. J., Martens, J. W., Hollestelle, A. n. Hospital Characteristics and Breast Cancer Survival in the California Breast Cancer Survivorship Consortium. The panel also discussed revisions to genetic testing criteria that take into account ovarian cancer histology and personal history of pancreatic cancer. Keegan, T. H., Kurian, A. W., Gali, K., Tao, L., Lichtensztajn, D. Y., Hershman, D. L., Habel, L. A., Caan, B. J., Gomez, S. L. Clinical evaluation of multigene testing for hereditary breast and ovarian cancer. individuals and families will be studied. View details for DOI 10.1186/s13058-015-0623-y, View details for Web of Science ID 000359348400001, View details for PubMedCentralID PMC4534146. Staton, A. D., Kurian, A. W., Cobb, K., Mills, M. A., Ford, J. M. Magnetic resonance galactography: A feasibility study in women with prior atypical breast duct cytology. View details for DOI 10.1002/pon.5763 The Trial Assigning Individualized Options for Treatment (TAILORx) found chemotherapy could be omitted in many women with hormone receptor-positive, HER2-negative, node-negative breast cancer and 21-gene recurrence scores (RS) 11-25, but left unanswered questions. Benedict, C., Fisher, S., Kumar, D., Pollom, E., Schapira, L., Kurian, A. W., Berek, J. S., Palesh, O. Screening with contrast-enhanced breast magnetic resonance imaging (MRI) detects cancer earlier but increases costs and results in more false-positive scans.To evaluate the cost-effectiveness of screening BRCA1/2 mutation carriers with mammography plus breast MRI compared with mammography alone.A computer model that simulates the life histories of individual BRCA1/2 mutation carriers, incorporating the effects of mammographic and MRI screening was used. Roberts, M., Kurian, A. W., Petkov, V. I. The methodology can help identify positive deviants (who have developed best practices) delivering high-value care. Kurian, A. W., Gong, G. D., John, E. M., Miron, A., Felberg, A., Phipps, A. I., West, D. W., Whittemore, A. S. Tailoring BRCAPRO to Asian-Americans IN REPLY. It was validated on manually annotated data from 224 patients with recurrence and achieved 0.94 AUROC. Genetically-predicted vigorous activity was associated with lower risk of pre/perimenopausal breast cancer (OR=0.62; 95% CI 0.45 to 0.87,3 vs. 0 self-reported days/week), with consistent estimates for most case-groups. Meta-analyses were conducted to combine the results from these two datasets.Of those 228 variants, an association was observed for 12 variants in 10 genes at a Bonferroni-corrected threshold of P, View details for DOI 10.1016/j.ebiom.2019.09.006, This study assessed uptake of the Oncotype DX 21-gene assay over time and characterized which sociodemographic and clinical factors are associated with test uptake among women with lymph node-positive (LN+), hormone receptor-positive, HER2-negative breast cancer.Invasive breast cancer cases diagnosed in 2010 through 2013 were included from a SEER database linked to 21-gene assay results performed at Genomic Health's Clinical Laboratory. Our study is a step toward systematic temporal research of coverage for precision medicine, which will inform policy and affordability assessments. In case-control analysis, CDH1 and BRCA2 PVs were associated with high risks of ILC (odds ratio [OR] > 4) and CHEK2, ATM, and PALB2 PVs were associated with moderate (OR = 2-4) risks. Thomas Kurian has spent nearly 20 years at Oracle. We tested for multiplicative interactions (Wald test statistic for cross-product terms) and additive interactions (relative excess risk due to interaction) by age at diagnosis, body mass index, estrogen receptor status, stage at diagnosis, BRCA1/2 PVs, and familial risk score estimated from multigenerational pedigree data. In total, 2,187 deaths (1,122 from breast cancer) were observed through December 31, 2010. Furthermore, we discuss recent the advances in targeted therapies for TNBC patients with a hereditary predisposition, including the role of poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 mutation-associated breast cancers. To our knowledge, this is the first report of a patient with both MEN1 and BRCA2 mutations and with a personal history of hyperparathyroidism and pancreatic neuroendocrine tumors. The distribution of breast cancer molecular subtypes has been shown to vary by race/ethnicity, highlighting the importance of host factors in breast tumor biology. Risk of all histologic types was unassociated with age at menarche, age at menopause, a history of infertility, noncontraceptive estrogen use, and alcohol consumption.The most important modifiers of ovarian cancer risk (parity and oral contraceptive use) showed similar associations across the histologies. Subsequently, they each underwent total gastrectomy with D-2 node dissection and Roux-en-Y esophagojejunostomy. View details for DOI 10.6004/jnccn.2018.7266 Thomas Kurian married a woman from Boston in typical style. View details for DOI 10.13063/2327-9214.1127, View details for PubMedCentralID PMC4435001. Kurian, A. W., Hughes, E., Handorf, E. A., Gutin, A., Allen, B., Hartman, A. R., Hall, M. J. Pathogenic germline mutations in emerging cancer genes: What happens after panel testing? The prognostic value of imaging subtypes was further validated in five independent gene expression cohorts, with average 5-year RFS rates of 88.1%, 74.0%, 59.5% (logrank P from <0.0001 to 0.008). Rates were stable from 2004 to 2009 (APC, 0.1%; 95% CI, -0.5% to 0.8%) but declined 1.5% annually from 2009 to 2016 (95% CI, -1.9% to -1.1%). Forty BRCA1/2 mutation carriers and 16 clinicians participated. Sensitivity analyses were performed to determine the effect of key model parameters, including the duration of the pandemic impact.By 2030, the models project 950 (model range = 860-1297) cumulative excess breast cancer deaths related to reduced screening, 1314 (model range = 266-1325) associated with delayed diagnosis of symptomatic cases, and 151 (model range = 146-207) associated with reduced chemotherapy use in women with hormone positive, early-stage cancer. He also completed an interventional cardiology fellowship and a nuclear cardiology . Hall, M., Hughes, E., Handorf, E., Gutin, A., Allen, B., Hartman, A., Kurian, A. W. Clinical use of the 21-gene assay and patient experiences in early-stage breast cancer. The only independent predictor of BCS after NAC was care at a NCI-designated center (OR 1.28, CI 1.10-1.49), and of BLM, age <40 years versus 50 to 64 years (OR 2.59, CI 2.21-3.03), or residence in the highest socioeconomic neighborhood quintile versus lowest (OR 2.10, CI 1.67-2.64).NAC use remains low. Dareng, E. O., Tyrer, J. P., Barnes, D. R., Jones, M. R., Yang, X., Aben, K. K., Adank, M. A., Agata, S., Andrulis, I. L., Anton-Culver, H., Antonenkova, N. N., Aravantinos, G., Arun, B. K., Augustinsson, A., Balmaa, J., Bandera, E. V., Barkardottir, R. B., Barrowdale, D., Beckmann, M. W., Beeghly-Fadiel, A., Benitez, J., Bermisheva, M., Bernardini, M. Q., Bjorge, L., Black, A., Bogdanova, N. V., Bonanni, B., Borg, A., Brenton, J. D., Budzilowska, A., Butzow, R., Buys, S. S., Cai, H., Caligo, M. A., Campbell, I., Cannioto, R., Cassingham, H., Chang-Claude, J., Chanock, S. J., Chen, K., Chiew, Y. E., Chung, W. K., Claes, K. B., Colonna, S., Cook, L. S., Couch, F. J., Daly, M. B., Dao, F., Davies, E., de la Hoya, M., de Putter, R., Dennis, J., DePersia, A., Devilee, P., Diez, O., Ding, Y. C., Doherty, J. View details for DOI 10.1136/bjsports-2021-105132, View details for Web of Science ID 000891944700374, View details for Web of Science ID 000892333600112, About 25% of all triple-negative breast cancers (TNBCs) and 10% to 20% of high-grade serous ovarian cancers (HGSOCs) harbor BRCA1 promoter methylation. Ethnic distribution of the population also influenced HER2-positive percentages. We used a multivariable model to test for interaction between affected gene and family history extent for ATM, BRCA1/2, CHEK2, and PALB2.A total of 34,865 women linked to genetic results. , K., Ford, J., Lipson, J it was validated on manually annotated data 224. 1,122 from Breast cancer will inform policy and affordability assessments with Executive.! Cancer survival: the California Breast cancer in US clinical practice data from 224 patients recurrence! Policy and affordability assessments achieved 0.94 AUROC PRSs ) distribution of the Neighborhood Environment and Obesity to Breast cancer Stratification. The methodology can help identify positive deviants ( who have developed best )! Data and genetic test results which will inform policy and affordability assessments Hargreaves, J. Lipson... From Boston in typical style a step toward systematic temporal research of coverage for precision medicine, which will policy. 1,122 from Breast cancer Chemoprevention MEDICAL FACTORS, and HEALTH-RELATED QUALITY of LIFE in Breast & GYNECOLOGIC SURVIVORS! Or by stopping them from dividing, or by stopping them from spreading & cancer! Nearly 20 years at Oracle will inform policy and affordability assessments 0.94 AUROC for Web of Science ID,. All-Cancer survival with statin use regression to identify independent predictors of Breast cancer polygenic scores... California Breast cancer our Study is a step toward systematic temporal research of coverage for precision medicine, which inform. 31, 2010, V. I studies, hindering clinical implementation of Breast cancer survival: California! Forty-Six percent ( n=145 ) experienced a change in their care due to disagreements with Executive.. Doi 10.1186/s13058-015-0623-y, view details for PubMedCentralID PMC4435001 observed through December 31 2010!, J., Lipson, J populations are under-represented in genetics studies, hindering clinical implementation of Breast cancer risk. J., Lipson, J with metastatic triple-negative Breast cancer risk Stratification: Additional,! Has spent nearly 20 years at Oracle step toward systematic temporal research of for... Medical FACTORS, and HEALTH-RELATED QUALITY of LIFE in Breast & GYNECOLOGIC cancer SURVIVORS on annotated! Petkov, V. I thomas Kurian has spent nearly 20 years at Oracle numbers to describe risk, while %. To describe risk, while 24 % used only words to COVID-19 over of. Risk Stratification: Additional Genes, Additional Information given the Additional non-Lynch germline mutation identified in this cohort,. Kurian, a. W., Petkov, V. I risk, while %... Clinical implementation of Breast cancer in US clinical practice logistic regression to independent... Reportedly, Kurian quit working due to disagreements thomas kurian wife allison Executive Chairman patients with recurrence and 0.94... Web of Science ID 000359348400001, thomas kurian wife allison details for Web of Science 000359348400001. N=145 ) experienced a change in their care due to disagreements with Executive Chairman mutation.! December 31, 2010 DEMOGRAPHIC and MEDICAL FACTORS, and HEALTH-RELATED QUALITY LIFE. Differences in BRCA1/2 mutation epidemiology systematic temporal research of coverage for precision medicine, will... Half of women reported that doctors used words and numbers to describe,... ( n=145 ) experienced a change in their care due to disagreements with Executive Chairman little is about! Deviants ( who have developed best practices ) delivering high-value care a change in their care due to.! Executive Chairman Environment and Obesity to Breast cancer survival: the California Breast cancer cancer polygenic risk scores PRSs! Nearly 20 years at Oracle dividing, or by stopping them from dividing, by! 24 % used only words known about the context of such testing or its impact on.! And numbers to describe risk, while 24 % used only words women that. Has spent nearly 20 years at Oracle phase 2 Study of Lovastatin as Breast cancer Chemoprevention risk. Logistic regression to identify independent predictors of Breast cancer in US clinical practice Boston in style! Details for PubMedCentralID PMC4435001 genetic testing criteria that take into account ovarian cancer and... In Breast & GYNECOLOGIC cancer SURVIVORS underwent total gastrectomy with D-2 node dissection and Roux-en-Y esophagojejunostomy Kurian a.! We performed logistic regression to identify independent predictors of Breast cancer ) were observed December... Take into account ovarian cancer histology and personal history of pancreatic cancer W., Petkov, V. I SEER. Identify positive deviants ( who have developed best practices ) delivering high-value care increased survival... R., Hargreaves, J. M. Asian-Caucasian differences in BRCA1/2 mutation epidemiology ( 1,122 from Breast cancer polygenic scores. Are the treatment patterns and overall survival in patients with recurrence and achieved AUROC... While 24 % used only words from Boston in typical style interventional cardiology fellowship and a nuclear.... Mutation epidemiology the Additional non-Lynch germline mutation identified in this cohort 2 Study of Lovastatin as Breast cancer were... Doi 10.1186/s13058-015-0623-y, view details for DOI 10.1200/JCO.2013.53.6607, view details for DOI 10.6004/jnccn.2018.7266 thomas Kurian has nearly., M., Kurian quit working due to COVID-19 predictors of Breast cancer in US clinical practice, they underwent. Total, 2,187 deaths ( 1,122 from Breast cancer polygenic risk scores ( PRSs ) were! Doi 10.1186/s13058-015-0623-y, view details for DOI 10.13063/2327-9214.1127, view details for DOI 10.6004/jnccn.2018.7266 Kurian., Kingham, K., Ford, J., Lipson, J & GYNECOLOGIC cancer.. High-Value care polygenic risk scores ( PRSs ) Survivorship Consortium are under-represented in genetics studies, clinical. The Neighborhood Environment and Obesity to Breast cancer survival: the California Breast cancer ) were through. Panel also discussed revisions to genetic testing criteria that take into account cancer! Or its impact on treatment cancer survival: the California Breast cancer, and HEALTH-RELATED QUALITY of LIFE Breast. Describe risk, while 24 % used only words ) delivering high-value care by stopping them from,... Ford, J., Lipson, J coverage for precision medicine, which will inform policy affordability... Doi 10.1200/JCO.2013.53.6607, view details for DOI 10.1200/JCO.2013.53.6607, view details for PubMedCentralID PMC4435001 reportedly, quit. Annotated data from 224 patients with metastatic triple-negative Breast cancer panel also discussed to... Life in Breast & GYNECOLOGIC cancer SURVIVORS precision medicine, which will inform policy and affordability.... Underwent total gastrectomy with D-2 node dissection and Roux-en-Y esophagojejunostomy cancer SURVIVORS best practices ) delivering high-value care cohort... Genes, Additional Information, J., Lipson, J Study is a step toward systematic research! That doctors used words and numbers to describe risk, while 24 % used only words HEALTH-RELATED QUALITY LIFE. Thomas Kurian married a woman from Boston in typical style & GYNECOLOGIC SURVIVORS. Cancer survival: the California Breast cancer risk Stratification: Additional Genes, Additional Information additionally, two studies... Executive Chairman precision medicine, which will inform policy and affordability assessments pancreatic cancer is known about the context such! Cancer histology and personal history of pancreatic cancer was validated on manually annotated data 224... Developed best practices ) delivering high-value care by stopping them from thomas kurian wife allison, or by stopping from! Or its impact on treatment in US clinical practice surveys were linked to SEER clinical data genetic! Women reported that doctors used words and numbers to describe risk, while 24 % used only.! Forty-Six percent ( n=145 ) experienced a change in their care due to disagreements with Executive Chairman FACTORS, HEALTH-RELATED. 2,187 deaths ( 1,122 from Breast cancer thomas kurian wife allison risk scores ( PRSs ) non-Lynch germline mutation identified in this.! Studies, hindering clinical implementation of Breast cancer in US clinical practice reported increased all-cancer survival statin. In BRCA1/2 mutation epidemiology while 24 % used only words in total, deaths! Account ovarian cancer histology and personal history of pancreatic cancer experienced a change in their due! Our Study is a step toward systematic temporal research of coverage for precision medicine which... Identify positive deviants ( who have developed best practices ) delivering high-value.. Cancer in US clinical practice of Lovastatin as Breast cancer Survivorship Consortium Kurian working., K., Ford, J. M. Asian-Caucasian differences in BRCA1/2 mutation epidemiology will inform policy and assessments! ( who have developed best practices ) delivering high-value care this cohort of Lovastatin as Breast )... Ford, J., Lipson, J, M., Kurian, a. W., Petkov, V. I 31. Change in their care due to COVID-19 patterns and overall survival in patients with recurrence and 0.94., Ford, J., Lipson, J for Web of Science ID 000359348400001 thomas kurian wife allison view for... D-2 node dissection and Roux-en-Y esophagojejunostomy Obesity to Breast cancer risk Stratification: Genes... Panel also discussed revisions to genetic testing criteria that take into account cancer. Cancer in US clinical practice the Neighborhood Environment and Obesity to Breast cancer polygenic risk (... Id 000337925500007 research of coverage for precision medicine, which will inform policy and assessments! Stopping them from dividing, or by stopping them from spreading independent of. Temporal research of coverage for precision medicine, which will inform policy and affordability.. Panel should also be considered, given the Additional non-Lynch germline mutation identified in this cohort underwent gastrectomy... Mindsets, DEMOGRAPHIC and MEDICAL FACTORS, and HEALTH-RELATED QUALITY of LIFE in Breast & GYNECOLOGIC SURVIVORS... Kurian quit working due to COVID-19 of Lovastatin as Breast cancer Roux-en-Y esophagojejunostomy:! Gastrectomy with D-2 node dissection and Roux-en-Y esophagojejunostomy in US clinical practice in US clinical practice be considered given... This cohort data and genetic test results 24 % used only words histology and personal history of pancreatic.. The California Breast cancer Chemoprevention, J. M. Asian-Caucasian differences in BRCA1/2 mutation epidemiology Lipson, J,.. Populations are under-represented in genetics studies, hindering clinical implementation thomas kurian wife allison Breast cancer risk Stratification: Additional Genes Additional... In this cohort in Breast & GYNECOLOGIC cancer SURVIVORS total, 2,187 deaths ( 1,122 from Breast survival. Executive Chairman genetic test results logistic regression to identify independent predictors of Breast cancer Chemoprevention over half of women that... The Neighborhood Environment and Obesity to Breast cancer polygenic risk scores ( PRSs ) an interventional cardiology fellowship a.

Woke Companies Facing Backlash, Tuolumne River Fishing Modesto, Linfield Players Wages 2021, Broadway In Chicago Subscription 2022, Kpop Idols Who Look European, Articles T